Rasmussen 1998.

Methods	Cross‐over randomised clinical trial.
Participants	Country: Denmark. Number randomised: 13. Post‐randomisation drop‐outs: not stated. Revised sample size: 13. Mean age: not stated. Females: not stated. Separate data for the subgroup with ulcerative colitis: no. Inclusion criteria: Diagnosis of primary sclerosing cholangitis. Raised alkaline phosphatase. Symptoms such as pruritus, pain, jaundice. Exclusion criteria: not stated. Follow‐up: 24 months.
Interventions	Participants were randomly assigned to 1 of 2 groups. Group 1: methotrexate (10 mg/m2 body area/wk) for the first year followed by placebo (n = 5). Group 2: placebo followed by methotrexate (10 mg/m2 body area/wk) (n = 8).
Outcomes	No outcomes of interest were reported before cross‐over.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: This information was not available.
Allocation concealment (selection bias)	Unclear risk	Comment: This information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: Trial authors stated double‐blind and have used placebo. However, the groups blinded were not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: Trial authors stated double‐blind and have used placebo. However, the groups blinded were not reported.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: This information was not available.
Selective reporting (reporting bias)	High risk	Comment: No published protocol was available; no outcomes of interest were reported.
For‐profit bias	Unclear risk	Comment: This information was not available.
Other bias	Low risk	Comment: no other bias.